Clinical trials: Reflux Esophagitis
Gastroesophageal Reflux Disease, Erosive Esophagitis
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents
The purpose of this study is to assess the safety and effectiveness of treatment with once daily oral administration of dexlansoprazole delayed-release capsules in adolescents with erosive esophagitis (EE) and for maintenance of…
- Trial name
- NCT01642615
- Testing
- Dexlansoprazole
- Where
- 60 sites in United States, Belgium and 6 more
- Volunteers
- 63 people
- Sponsor
- Takeda
Gastroesophageal Reflux Disease, Reflux Esophagitis
The Efficacy of i-Scan for Detecting Reflux Esophagitis
Endoscopy is a widely used modality for the diagnosis and classification of Gastroesophageal reflux disease (GERD), and the extent of esophageal mucosal breaks on endoscopy can be assessed.
- Trial name
- NCT01381991
- Testing
- i-scan
- Where
- South Korea
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Konkuk University Hospital
Erosive Esophagitis, Heartburn
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
The main objective of the study is to compare the maternal, fetal, and infant outcomes of pregnant women who are exposed to vonoprazan during pregnancy with outcomes of an internal comparison cohort of pregnant women who are…
- Conditions
- Erosive Esophagitis, Heartburn, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Helicobacter Pylori Infection
- Trial name
- NCT06660342
- Testing
- Vonoprazan
- Where
- United States
- Volunteers
- 728 people
- Sponsor
- Phathom Pharmaceuticals, Inc.
Gastroesophageal Reflux Disease
Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI
The purpose of this project is to compare the efficacy (how successful) 1) standard-dose proton pump inhibitor (PPI) (rabeprazole 20 mg once daily) (a medication that completely blocks the stomach from producing acid) plus low…
- Trial name
- NCT00539240
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- US Department of Veterans Affairs
Reflux Disease, Gastro-Esophageal, Hiatal Hernia
Treatment of Reflux With Sleeve Gastrectomy
In 2008, the World Health Organization (WHO) report found that 0.5-1.5 billion people aged 20 years and above suffer from overweight (body mass index (BMI) ≥ 25) and obesity (BMI ≥ 30 kg / m2) stated.
- Conditions
- Reflux Disease, Gastro-Esophageal, Hiatal Hernia, Reflux Esophagitis
- Trial name
- NCT06170060
- Testing
- Laparoscopic Sleeve Gastrectomy
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Yusuf Emre ALTUNDAL
Gastro-esophageal Reflux Disease, Non-erosive Reflux Disease
Detection of Minimal Change Esophagitis by I-scan
Study design and objective The primary outcome of this prospective cohort study was to identify the endoscopic findings that have diagnostic value for the prediction of NERD (minimal change esophagitis) by using HD endoscopy with…
- Trial name
- NCT01560910
- Where
- Thailand
- Volunteers
- 48 people
- Sponsor
- arpa pungrasamee
Esophagus Cancer, Esophageal Cancer Stage
A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma
This study aims to develop a highly sensitive, specific, and cost-effective blood assay for the early detection of esophageal adenocarcinoma and its precursor lesions, using advanced machine learning and state-of-the-art…
- Conditions
- Esophagus Cancer, Esophageal Cancer Stage, Esophageal Cancer, Esophageal Neoplasms
- Trial name
- EMERALD (NCT06381583)
- Testing
- EMERALD (Esophageal MicroRNAs for BaRRett's esophagus, Adenocarcinoma, and Dysplasia)
- Where
- United States
- Volunteers
- 658 people
- Sponsor
- City of Hope Medical Center
Eosinophilic Esophagitis, Gastroesophageal Reflux
Phenotypic Characterization and Biomarkers Investigation for Eosinophilic Esophagitis in Pediatric Patients
The purpose of this study is to find out some potential biomarkers for the Eosinophilic Esophagitis (EoE) in pediatric patients through the prospective clinical characterization and assessment of samples collected during the…
- Trial name
- NCT03069573
- Where
- Brazil
- Volunteers
- 110 people
- Sponsor
- Federal University of Uberlandia
Healthy Volunteers
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Human: A Single/Multiple Ascending Dose Study
The purpose of this study is to assess and analyze the safety, tolerability and PK/PD data following single ascending and multiple ascending doses of X842 in healthy subjects.
- Trial name
- NCT03105375
- Testing
- Single ascending dose of X842, Multiple ascending dose of X842, Losec
- Where
- Sweden
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Cinclus Pharma Holding AB
GORD, Oesophageal Cancer
The Bacterial Composition of the Stomach in Reflux Disease
Gastric and oesophageal (OG) cancer associated with poor long term outcome as overall less than 25% of patients survive for more than 5 years due to late recognition of the disease.
- Conditions
- GORD, Oesophageal Cancer, Oesophageal Reflux, Gastric Cancer
- Trial name
- NCT03835663
- Testing
- No intervention but patients are undergoing an upper GI endoscopy and biopsies for clinical purposes
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Imperial College London
Esophagitis, Reflux Esophagitis
The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis
The purpose of this study is to determine the role of hypoxia inducible factor (HIF)-2a on the production of inflammatory cytokines that lead to reflux esophagitis.
- Conditions
- Esophagitis, Reflux Esophagitis, Gastroesophageal Reflux Disease
- Trial name
- NCT01733810
- Testing
- Cessation of Acid Suppressing Medications
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Dallas VA Medical Center
Reflux Oesophagitis
Safety, Tolerability and Pharmacokinetics of Single Rising Doses of YF476, a Gastrin Antagonist, in Healthy Men
The objectives of the study were: To assess the safety, tolerability and pharmacokinetics of YF476 in healthy volunteers. To select a dose or doses of YF476 for detailed pharmacodynamic studies in healthy volunteers.
- Trial name
- NCT01538784
- Testing
- YF476
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
Reflux Esophagitis
Reflux Esophagitis Phase III Study (Initial Treatment)
This study is to evaluate the efficacy of esomeprazole 20 mg once daily and 40 mg once daily for 8 weeks on healing of Reflux Esophagitis in patients with reflux esophagitis in comparison with omeprazole 20 mg once daily by…
- Trial name
- NCT00633932
- Testing
- Esomeprazole, Omeprazole
- Where
- 41 sites in Japan
- Volunteers
- 602 people
- Sponsor
- AstraZeneca
GERD
High Definition Endoscopy With NBI. Contribution in Patients With Non-erosive Esophagitis
Most patients with symptomatic gastroesophageal reflux disease (GERD) have a normal upper gastrointestinal endoscopy. Attempts have been made to define new endoscopic techniques for identification of abnormalities non detected in…
- Trial name
- NCT03824431
- Testing
- Endoscopic esophageal biopsies
- Volunteers
- 70 people
- Sponsor
- University of Sao Paulo General Hospital
Esophageal Disease
Efficacy of DA-5204 on Gastroesophageal Reflux Disease
This is a single-center, randomized, double-blind, placebo-controlled clinical Study to evaluate the efficacy of DA-5204 and proton pump inhibitor combination therapy compared with proton pump inhibitor alone therapy in patients…
- Trial name
- NCT03998969
- Testing
- Pantoprazole, DA-5204
- Where
- South Korea
- Volunteers
- 70 people
- Sponsor
- Seoul National University Hospital
Acid Reflux Esophagitis, Non-acid Reflux Esophagitis
Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy
Somatostatine induces a dose-dependent reduction of postprandial plasma cholecystokinin (CCK) secretion with a concomitant inhibition of postprandial gallbladder contraction, abolishing almost completely bile salts output from…
- Trial name
- NCT02054637
- Testing
- Lanreotide
- Where
- Belgium
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Gastroparesis, GERD
Domperidone for Relief of Gastrointestinal Disorders
The purpose of this study is to make Domperidone available to patients with gastrointestinal disorders who have failed standard therapy and who might benefit from it.
- Conditions
- Gastroparesis, GERD, Esophagitis, Dyspepsia
- Trial name
- NCT00761254
- Testing
- Domperidone
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Carle Physician Group
Gastroesophageal Reflux Disease (GERD), Eosinophilic Esophagitis (EoE)
Mucosal Impedance in Pediatric Population
Our hypothesis is that patients with GERD and/or Eosinophilic Esophagitis (EE) have lower esophageal impedance measurements when compared to patients who do not have GERD or EE.
- Conditions
- Gastroesophageal Reflux Disease (GERD), Eosinophilic Esophagitis (EoE), Functional Dyspepsia
- Trial name
- NCT02320981
- Testing
- Standard of Care esophagogastroduodenoscopy (EGD) with measurement of mucosal impedance
- Where
- United States
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Gastroesophageal Reflux
The Need of Revisiting to an Outpatient Clinic After the Prescription of Vonoprazan or Esomeprazole
After vonoprazan (20mg/day) or esomeprazole (20mg/day) for 4weeks is prescribed for patients with erosive esophagitis diagnosed by esophagogastroduodenoscopy, the number of patients who will visit our outpatient clinic again due…
- Trial name
- NCT04720781
- Testing
- Vonoprazan, Esomeprazole
- Where
- Japan
- Volunteers
- 300 people
- Sponsor
- Showa Inan General Hospital
Reflux Esophagitis
Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes
The objective of this investigation is to collect following data in patients given NEXIUM capsule (NEXIUM) in usual post-marketing use.
- Trial name
- NCT02477475
- Where
- 47 sites in Japan
- Volunteers
- 1,595 people
- Sponsor
- AstraZeneca